Synergistic effect of CH-296 and interferon gamma on cytokine-induced killer cells expansion for patients with advanced-stage malignant solid tumors

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 4, 2011, Pages 485-494

  Yu, Jinpu ^a   Ren, Xiubao ^a   Li, Hui ^a   Cao, Shui ^a   Han, Ying ^a   Enoki, Tatsuji ^b   Kato, Ikunoshin ^b   Cao, Chunyu ^c   Hao, Xishan ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TAKARA BIO INC   (Japan)

^c Takara Biomedical Technology Co Ltd   (China)

Author keywords

adoptive immunotherapy; cytokine induced killer cells; fibronectin; interferon gamma; solid tumor

Indexed keywords

ANTINEOPLASTIC AGENT; CH 296; CYTOKINE; GAMMA INTERFERON; RECOMBINANT HUMAN FIBRONECTIN FRAGMENT; RETRONECTIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE INDUCED KILLER CELL; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG POTENTIATION; DRUG RESPONSE; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; SOLID TUMOR; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL LINE, TUMOR; CYTOKINE-INDUCED KILLER CELLS; FEMALE; FIBRONECTINS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; MALE; MIDDLE AGED; NEOPLASMS; RECOMBINANT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80051734670     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2010.0927     Document Type: Article

References (28)

1. Olioso P, Giancola R, Di Riti M, et al. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: A pilot clinical trial. Hematol Oncol 2009;27:130.
2. Li H, Wang C, Yu J, et al. Dendritic cell-activated cytokineinduced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy 2009;11:1076.
3. Linn YC, Lau SK, Liu BH, et al. Characterization of the recognition and functional heterogeneity exhibited by cytokine- induced killer cell subsets against acute myeloid leukaemia target cell. Immunology 2009;126:423.
4. Leemhuis T, Wells S, Scheffold C, et al. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005;11:181.
5. Schmidt-Wolf GD, Negrin RS, Schmidt-Wolf IG. Activated T cells and cytokine-induced CD3 + CD56 + killer cells. Ann Hematol 1997;74:51.
6. Lu PH, Negrin RS. A novel population of expanded human CD3 + CD56 + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1997;153:1687.
7. Ren X, Yu J, Liu H, et al. Th1 bias in PBMC induced by multicycles of auto-CIKs infusion in malignant solid tumor patients. Cancer Biother Radiopharm 2006;21:22.
8. Yu J, Ren X, Cao S, et al. Th1 polarization and apoptosisinducing activity of CD4 + T -cells in cytokine-induced killers might favor the antitumor cytotoxicity of cytokine-induced killers in vivo. Cancer Biother Radiopharm 2006;21:276.
9. Erhardt M, Schmidt-Wolf IG, Sievers E, et al. Anti-tumoral capabilities of effector cells after IFN-alpha or CpG-motif treatment of cocultured dendritic cells. Arch Immunol Ther Exp (Warsz) 2006;54:403.
10. Yu J, Zhang W, Jiang H, et al. CD4 + T cells in CIKs (CD4 + CIKs) reversed resistance to Fas-mediated apoptosis through CD40/CD40L ligation rather than IFN-G stimulation. Cancer Biother Radiopharm 2008;23:342.
11. Nishimura R, Baker J, Beilhack A, et al. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 2008;112:2563.
12. Refaeli Y, Van Parijs L, Alexander SI, et al. Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med 2002;196:999.
13. Akkoc T, de Koning PJ, Rückert B, et al. Increased activationinduced cell death of high IFN-gamma-producing T(H)1 cells as a mechanism of T(H)2 predominance in atopic diseases. J Allergy Clin Immunol 2008;121:652.
14. Hynes RO. Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11.
15. Sturm A, Krivacic AK, Fiocchi C, et al. Dual function of the extracellular matrix: Stimulatory for cell cycle progression of naive T cells and antiapoptotic for tissue-derived memory T cells. J Immunol 2004;173:3889.
16. Gendron S, Couture J, Aoudjit F. Integrin alpha2beta1 inhibits Fas-mediated apoptosis in T lymphocytes by protein phosphatase 2A-dependent activation of the MAPK/ERK pathway. J Biol Chem 2003;278:48633.
17. Kimizuka F, Taguchi Y, Ohdate Y, et al. Production and characterization of functional domains of human fibronectin expressed in Escherichia coli. J Biochem 1991;110:284.
18. Yu SS, Nukaya I, Enoki T, et al. In vivo persistence of genetically modified T cells generated ex vivo using the fibronectin CH296 stimulation method. Cancer Gene Ther 2008; 15:508.
19. Tsuchida Y, Therasse P. Response evaluation criteria in solid tumors (RECIST): New guidelines. Med Pediatr Oncol 2001; 37:1.
20. Zhang YS, Yuan FJ, Jia GF, et al. CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R. World J Gastroenterol 2005;11:3339.
21. Liu P, Chen L, Huang X. The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo. Cancer Biother Radiopharm 2009;24:91.
22. Nojima Y, Humphries MJ, Mould AP, et al. VLA-4 mediates CD3-dependent CD4 + T cell activation via the CS1 alternatively spliced domain of fibronectin. J Exp Med 1990;172:1185.
23. Nojima Y, Rothstein DM, Sugita K, et al. Ligation of VLA-4 on T cells stimulates tyrosine phosphorylation of a 105-kD protein. J Exp Med 1992;175:1045.
24. Sato T, Tachibana K, Nojima Y, et al. Role of the VLA-4 molecule in T cell co-stimulation. Identification of the tyrosine phosphorylation pattern induced by the ligation of VLA-4. J Immunol 1995;155:2938.
25. Boehm U, Klamp T, Groot M, et al. Cellular responses to interferon-gamma. Annu Rev Immunol 1997;15:749.
26. Takeda K, Hayakawa Y, Smyth MJ, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001;7:94.
27. Linn YC, Hui KM. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia. Leuk Lymphoma 2003;44:1457.
28. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: Function, generation and maintenance. Annu Rev Immunol 2004;22:745.